Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down – Here’s Why

Posted by Brian Himes on Jun 10th, 2026

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $84.57, but opened at $72.90. Dianthus Therapeutics shares last traded at $72.07, with a volume of 790,177 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group set a $98.00 target price on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 9th. William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Oppenheimer raised their price target on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a report on Monday, March 9th. Wedbush raised their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $117.82.

Check Out Our Latest Report on Dianthus Therapeutics

Dianthus Therapeutics Price Performance

The firm has a fifty day simple moving average of $87.36 and a two-hundred day simple moving average of $64.45. The firm has a market capitalization of $3.84 billion, a P/E ratio of -17.00 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. On average, research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Activity

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 8,224 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $89.84, for a total value of $738,844.16. Following the completion of the transaction, the executive vice president owned 8,224 shares of the company’s stock, valued at $738,844.16. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Edward Carr sold 43,682 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 349,551 shares of company stock worth $28,968,156. Insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Fairmount Funds Management LLC raised its holdings in Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after purchasing an additional 600,000 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP increased its stake in Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. increased its stake in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC increased its stake in Dianthus Therapeutics by 11.7% during the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.